CytoMed Therapeutics Ltd

GDTC Nasdaq SEC CIK 1873093
Follow CytoMed Therapeutics Weekly email: filings, results

Financials

Reported figures only · latest: Q4 2025 SGD · IFRS
EPS, diluted -

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, IFRS
Revenue and net income7 fiscal years
−SGD 6M−SGD 4M−SGD 2MSGD 0FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearNet income
FY25−SGD 4M
FY24−SGD 2.5M
FY23−SGD 4.1M
FY22−SGD 3.1M
FY21−SGD 2.1M
FY20−SGD 1.9M
FY19-
Free cash flowOperating cash flow minus capital expenditure
−SGD 6M−SGD 4M−SGD 2MSGD 0FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearFree cash flow
FY25−SGD 4.3M
FY24−SGD 4.1M
FY23−SGD 3.6M
FY22−SGD 1.9M
FY21−SGD 2.3M
FY20−SGD 1.1M
FY19-